On Wednesday, RBC Capital maintained its Outperform rating on Exelixis (NASDAQ:EXEL) shares and increased the price target to $34 from $30. The adjustment follows a recent court decision that upheld the patent protection for the company's cancer drug, Cabometyx (Cabo), extending its market exclusivity until 2030.
The analyst at RBC Capital highlighted the significance of the ruling, stating it provides a "refreshed forward-orienting set-up for shares." The decision is expected to prevent generic competition for Cabometyx until the end of the decade, thereby bolstering the drug's revenue potential. This extension of exclusivity was factored into the analyst's valuation model, adding an estimated $4 per share in value.
Exelixis is anticipated to benefit from the delayed patent cliff, now projected to occur in 2030 or 2031, instead of the previously expected 2027 or 2028. This provides the company with a more extended period to diversify its pipeline through internal innovation with treatments like zanza and XL309, as well as targeted business development (BD) efforts in genitourinary (GU), gastrointestinal (GI), and thoracic oncology.
According to the analyst, the prolonged exclusivity for Cabometyx enhances the present value of the drug and improves the outlook for Exelixis' stock. The company is poised to leverage Cabometyx's extended market protection to advance its pipeline and pursue strategic BD activities, which are now seen as the primary narratives driving the value of Exelixis shares.
In other recent news, Exelixis Inc . has experienced significant developments. The biopharmaceutical company won a key legal victory, with the U.S. District Court upholding the validity of three patents related to its drug product, effectively blocking a generic version from entering the market until at least January 2030. This ruling is expected to protect Exelixis' market exclusivity for the drug for several more years.
Exelixis's Q2 revenues reached $637.2 million, largely driven by its leading product, cabozantinib, which contributed $437.6 million. The company has also initiated a clinical development partnership with Merck to assess the efficacy of a new investigational cancer treatment. This collaboration involves a phase 3 trial for head and neck squamous cell carcinoma and multiple trials for renal cell carcinoma.
Analysts from firms such as Citi and H.C. Wainwright have reaffirmed their Buy rating on Exelixis shares, following the presentation of positive results from various Phase 3 trials. However, Goldman Sachs maintains a Sell rating on Exelixis, citing ongoing concerns over the company's revenue growth prospects post-2030. These are recent developments in the company's journey.
InvestingPro Insights
The recent court decision upholding Cabometyx's patent protection aligns well with several InvestingPro metrics and tips for Exelixis (NASDAQ:EXEL). The company's strong financial position is evident from its market cap of $8.13 billion and robust revenue growth of 17.48% over the last twelve months as of Q2 2024. This growth is further emphasized by an impressive quarterly revenue increase of 35.61% in Q2 2024.
InvestingPro Tips highlight that Exelixis "holds more cash than debt on its balance sheet" and has "liquid assets exceed short term obligations," suggesting a solid financial foundation to support its extended market exclusivity for Cabometyx. Moreover, the tip that "net income is expected to grow this year" aligns with the positive outlook following the patent ruling.
The company's stock performance has been noteworthy, with InvestingPro Data showing a 25.22% price total return over the last three months and trading near its 52-week high. This performance likely reflects market optimism about the extended patent protection and Exelixis' future prospects.
For investors seeking more comprehensive analysis, InvestingPro offers 12 additional tips for Exelixis, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.